A randomized trial evaluating vitamin K therapy with aspirin or placebo with a left ventricular assist device shows avoiding aspirin reduced bleeding without increasing thrombotic risk.
Dual antiplatelet therapy with prasugrel seemed as safe and effective as primary treatment and as a substitute for other P2Y12 inhibitors in a real-world Korean registry.
The Task Force advises against starting aspirin for primary prevention in people aged 60 years or over and suggests the decision should be individualized in those aged 40-59.
A randomized, open-label trial showed improved clinical outcomes from a low dose of direct oral anticoagulant in patients at high risk for venous thromboembolism and low risk for bleeding.